

## Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in this application:

### Listing of Claims

1. – 11. (Canceled)

12. (currently amended) A method of treating neuralgia pain, also known as neuropathic pain, in a mammal, including a human, ~~pains which are accompanied by an increase in muscle tone~~, comprising administering to a patient in need thereof a therapeutically effective amount of a combination of retigabine or a therapeutically utilizable salt thereof with a sodium channel-inhibiting or -influencing substance or a therapeutically utilizable salt thereof.

13. (previously presented) The method of claim 12, wherein said sodium channel-inhibiting or -influencing substance is selected from tolperisone, eperisone, silperisone, riluzole, propafenone, lidocaine, flecainide, and metixen, or pharmaceutically utilizable salts thereof.

14. (previously presented) The method of claim 12, wherein said sodium channel-inhibiting or -influencing substance is selected from tolperisone, eperisone, silperisone, and other tolperisone analogs, and pharmaceutically utilizable salts thereof.

15. (currently amended) A method of treating neuralgia pain, also known as neuropathic pain, in a mammal, including a human, ~~pains which are accompanied by an increase in muscle tone~~, comprising administering to a patient in need thereof a therapeutically effective amount of a combination of retigabine with tolperisone, eperisone, silperisone, or another tolperisone analog, or a pharmaceutically utilizable salt thereof.

16-22. (withdrawn)

23. (previously presented) The method of claim 12, where said combination is administered orally, rectally, intravenously, transdermally, subcutaneously, or intracutaneously.

24. (previously presented) The method of claim 12, wherein said sodium channel-inhibiting or -influencing substance or therapeutically utilizable salt thereof is administered simultaneously with retigabine.

25. (previously presented) The method of claim 12, wherein retigabine, or a therapeutically utilizable salt thereof, and said sodium channel-inhibiting or -influencing substance are administered separately or consecutively.